key: cord-0721760-9xftbgqg
authors: Chan, W. Y.; Zhu, C.; Sanchez, E.; Gupta, R.; Fielding, A. K.; Khwaja, A.; Payne, E. M.; O'Nions, J.
title: Antibody responses to SARS-CoV-2 vaccination in patients with acute leukaemia and high risk MDS on active anti-cancer therapies
date: 2022-04-06
journal: nan
DOI: 10.1101/2022.04.05.22273371
sha: be5bd927e4488be77a8c8e226a2915678c5d73be
doc_id: 721760
cord_uid: 9xftbgqg

Patients with haematological malignancies, such as acute leukaemia and high-risk MDS (HR-MDS), have significantly increased mortality and morbidity from COVID-19. However vaccine efficacy in these patients and the impact of systemic anti-cancer therapy (SACT) on vaccine response remains to be fully established. SARS-CoV-2 antibody responses in 53 patients with ALL, AML or HR-MDS receiving SACT were characterised following two doses of either BNT162b2 or ChAdOx1nCoV-19. All patients were tested for anti-S antibodies after 2 doses, 60% after the first dose and anti-N antibody testing was performed on 46 patients (87%). Seropositivity rates after 2 vaccine doses were 95% in AML/HR-MDS patients and 79% in ALL. After stratification by prior SARS-CoV-2 infection, naive patients with AML/HR-MDS had higher seroconversion rates and median anti-S antibody titres compared to ALL (median 291U/mL versus 5.06U/mL), and significant increases in anti-S titres with consecutive vaccine doses, not seen in ALL. No difference was seen in serological response between patients receiving intensive chemotherapy or non-intensive therapies (HMA) but significantly reduced titres were present in AML/HR-MDS patients who received venetoclax-based regimens compared to other therapies. All ALL patients received intensive chemotherapy, with no further impact of anti-CD20 immunotherapy on serological response. Understanding the impact of disease subtypes and therapy on vaccine response is essential to enable decisions on modifying or delaying treatment in the context of either SARS-CoV-2 infection or vaccination.

SARS-CoV-2 vaccination represents an important measure to protect the population from 31 showing excellent rates of seroconversion and efficacy in preventing severe disease 1,2 . However, 32 vaccine efficacy remains to be fully-established in patients with haematological malignancy who have 33 significantly increased mortality and morbidity from 4, 5 . Variable humoral responses to 34 SARS-CoV-2 vaccination have been reported, with the lowest seroconversion rates in patients with B-35 cell malignancies and those receiving systemic anti-cancer therapy (SACT) 6, 7, 8, 9 . Encouraging 36 seroconversion rates in patients with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia 37 (AML) and HR-MDS have been reported within larger cohort studies of patients with a variety of 38 haematological cancers 7,10,11,12 . However, the impact of SACT on vaccine responses in patients with 39 ALL, AML and high-risk myelodysplastic syndrome (HR-MDS) remains unclear, but has important 40 implications for clinical management. Here we have addressed this and report SARS-CoV-2 antibody 41 responses following vaccination in patients with ALL, AML or HR-MDS receiving SACT . 42 43

Demographics, SACT history and laboratory parameters were collected from electronic health records 45 for patients with acute leukaemias and HR-MDS receiving or recently completed SACT, who had two 46 doses of SARS-CoV-2 vaccine between December 2020 and July 2021 47 (with 8 to 12 weeks between doses as per UK vaccination programme). Serological testing was 48 performed using the Roche Elecsys anti-SARS-CoV-2 enzyme immunoassays. All patients were 49 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 6, 2022. anti-S antibodies after 2 doses (median 43 days post-dose) and 60% after first dose (median 37.5 days). 61

A trend towards higher rates of seropositivity was seen in AML and HR-MDS compared to ALL after 2 62 doses (95% compared to 79%, p=0.06, Figure 1A ). The seropositivity rate after dose one in all patients 63 was 75% (median anti-S titre 7.275U/ml ), rising to 91% following dose two (median 64 249U/ml [IQR 24.95-1721] ), Figure 1B . There was no significant difference in anti-S seropositivity rate 65 or median antibody titre after dose one between patients with AML/HR-MDS and ALL (74% vs 78% 66 seropositive, median titres 5.90U/ml ] versus 11.4U/ml [IQR 0.61-1380] To define vaccine-induced seroconversion, we analysed responses in patients with no prior SARS-CoV-71 2 infection and negative anti-N serology ( Figure 1C , Figure S1A ). Anti-S seroconversion was 91% with 72 median titre of 132U/mL . Seroconversion rates and median titres in SARS-CoV-2 naïve 73 patients remained higher in the myeloid compared to lymphoid cohort (median 235U/mL . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. [IQR 574.5-2500] , although this did not reach significance (p=0.77) ( Figure 1G , 80 Figures S1D,E). This is consistent with reports of higher overall post-vaccination antibody titres in 81 individuals with prior natural infection 13, 14 . 82

Next we investigated the impact of SACT type on serological responses. No significant difference in 83 seropositivity or antibody titres was seen in AML/HR-MDS patients receiving intensive (30% patients) 84 compared to non-intensive chemotherapy (azacitidine, 23%); however, anti-S titres were significantly 85 reduced in patients on venetoclax-based regimens (51% of myeloid patients, median 158.5U/mL , p=0.04). This was independent of previous SARS-CoV-2 infection ( Figure 1H , Figure S2A ). 87

The majority of ALL patients (79%) received intensive treatment (as per current UKALL protocols) and 88 had low anti-S titres post vaccination ( Figure 1A ,B,C,F). Anti-B cell directed therapy is associated with 89 poor serological response to SARS-CoV-2 vaccination. Five ALL patients received Rituximab but no 90 effect was seen on anti-S response, albeit in small numbers ( Figure S2B ,C). 91

Here we report the majority of patients with acute leukaemias and HR-MDS develop detectable anti-92 S antibodies following two doses of SARS-CoV-2 vaccine, with seropositivity rates of 91%. SARS-CoV-93 2 naïve patients with AML/HR-MDS showed significantly increased antibody responses following 94 consecutive vaccine doses, whereas ALL patients tended towards very low titres with a minimal 95 increase, and it remains to be established whether this is sufficient to confer protective immunity. 96

While patients with acute leukaemias can generate robust serological responses to natural infection, 97 this was not the case for all patients following vaccination, highlighting the importance of measuring 98 antibody titres, not just seropositivity, and to consider prior SARS-CoV-2 infection influencing vaccine 99 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. anti-CD20 and anti-CD19 immunotherapies) have been reported in mature B-cell neoplasms and 103 myeloma, but not acute leukaemias 6, 9, 11, 15 . While we found no significant difference in antibody titres 104 or seroconversion in AML/HR-MDS patients receiving intensive or non-intensive therapy, patients 105 receiving venetoclax-based regimens showed reduced antibody levels. Notably, ALL with intensive 106 chemotherapy displayed almost uniformly low antibody titres (<10U/ml) after two vaccine doses, 107 regardless of additional B-cell directed therapy. We propose that further work to define correlates of 108 vaccine protection (humoral and T cell responses), the impact of SACT regimens on the 109 magnitude/duration of responses, and the value of additional booster doses will have clear 110 implications for this vulnerable group and should be priority questions for larger prospective studies. 111

Contributions 113 JO conceived of the study, performed data collection, data analysis, literature search, and manuscript 114 writing and revision; WC data collection, data analysis, manuscript writing, and revision; CZ performed 115 data collection, manuscript review and revision; EP conceived of study, manuscript review and 116 revision; ES data collection, manuscript review and revision; AF, AK, RG, manuscript review and 117 revision. 118

Acknowledgements 120

We are extremely grateful to all the patients who participated in this study and to the NHS staff that 121 provided their clinical care. EMP is supported by a CRUK Advanced Clinician Scientist Fellowship (Grant 122 No. A24873). RG acknowledges funding from Cure Cancer@ UCL. 123 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. 145 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. as ≥0.8U/mL, upper limit of the assay >2500U/ml *lower limit of assay, **upper limit of assay. 1A: 168

Seropostivity for anti-S antibodies in all patients following two doses of SARS-CoV-2 vaccine, 169 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.05.22273371 doi: medRxiv preprint 

Median titres post first dose in all patients U/mL (IQR) 7.275 U/mL (0

Median titres post first dose in patients with negative baseline U/mL (IQR)

Median titres post second dose in all patients U/mL (IQR)

Median titres post second dose in patients with negative baseline U/mL (IQR)

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.05.22273371 doi: medRxiv preprint